"Vasoactivators"--a new concept for naturally secreted vasoconstrictor substances

Area of Science:

• Cardiovascular Physiology
• Endothelial Function
• Pharmacology

Background:

• Many vasoconstrictors paradoxically induce vasodilation via endothelium-derived relaxing factor (EDRF).
• The hypothesis posits that all endogenous vasoconstrictors may act as vasodilators to regulate vascular tone.
• Thromboxane A2 (TXA2), a platelet-derived vasoconstrictor, was investigated for its EDRF-stimulating potential.

Purpose of the Study:

• To determine if thromboxane A2 (TXA2) stimulates endothelium-derived relaxing factor (EDRF) release.
• To test the hypothesis that naturally secreted vasoconstrictors can also be vasodilators.
• To propose a new classification for vasoactive substances based on their constrictive and relaxing effects.

Main Methods:

• Utilized U46619, a stable analog of thromboxane A2 (TXA2), in porcine coronary arteries (CA).
• Investigated the effect of U46619 on EDRF biosynthesis and release.
• Employed NG-nitro-L-arginine (L-NNA), an EDRF synthesis inhibitor, to block the observed effects.

Main Results:

• U46619 was confirmed as a stimulus for EDRF biosynthesis and release in porcine coronary arteries.
• The EDRF-mediated vasodilatory effect of U46619 was blocked by NG-nitro-L-arginine (L-NNA).
• Results support the hypothesis that vasoconstrictors can also induce vasodilation.

Conclusions:

• Naturally secreted vasoconstrictors may function as vasodilators through EDRF release, supporting the
• vasoactivator
• concept.
• Vasoactivators can be classified into types based on predominant constrictive or balanced effects on endothelium-intact and denuded arteries.
• Understanding these dual actions is crucial for maintaining physiological vascular tone.